Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03956225 · ClinicalTrials.gov registry record · NA

Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study

A NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye Disease, sponsored by Alcon Research.

Completed
Registry status
NA
Development phase
299
Enrollment target
15
Study locations

NCT03956225 is a NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye Disease that has completed, run by Alcon Research. The registered enrollment target is 299 participants, above the 65-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (360% higher). The trial reports 15 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03956225, a NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye Disease, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
NA
Development phase
299 participants
Enrollment target
15
Study locations

Study Summary

The purpose of this post-approval study is to demonstrate that iLux treatment offers comparable treatment effectiveness to LipiFlow for MGD treatment at 12 months post single treatment.

Conditions Studied

Meibomian Gland Dysfunction Evaporative Dry Eye Disease

Interventions

  • DEVICE Systane iLux® Dry Eye System
  • DEVICE LipiFlow® Thermal Pulsation System

Study Locations (15)

California

  • Alcon Investigator 9083 - Long Beach
  • Alcon Investigator 9081 - Los Angeles
  • Alcon Investigator 9084 - San Diego

Ohio

  • Alcon Investigator 8046 - Granville
  • Alcon Investigator 6313 - Powell

Florida

  • Alcon Investigator 5127 - Panama City

Illinois

  • Alcon Investigator 4782 - Highland Park

Kansas

  • Alcon Investigator 6567 - Pittsburg

Kentucky

  • Alcon Investigator 5582 - Louisville

Minnesota

  • Alcon Investigator 6402 - Medina

Missouri

  • Alcon Investigator 1455 - Kansas City

Trial Details

FieldValue
Enrollment Target 299 participants
Start Date 2019-06-25
Est. Completion 2020-10-24
Phase NA

Sponsor

Alcon Research

275 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03956225

The ClinicalTrials.gov registry entry for NCT03956225 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (360% higher). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Systane iLux® Dry Eye System is the first listed.

NCT03956225 reports 15 study locations spanning 12 distinct geographic areas - top geographies include California, Ohio, Florida.

Frequently Asked Questions

What is clinical trial NCT03956225 about?

NCT03956225 is a clinical study titled "Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study". The purpose of this post-approval study is to demonstrate that iLux treatment offers comparable treatment effectiveness to LipiFlow for MGD treatment at 12 months post single treatment.

What is the current status of trial NCT03956225?

This trial is currently completed. It is a NA study. The enrollment target is 299 participants. The study started on 2019-06-25. Estimated completion is 2020-10-24.

What conditions does trial NCT03956225 study?

This clinical trial studies the following conditions: Meibomian Gland Dysfunction, Evaporative Dry Eye Disease.

What interventions are being tested in trial NCT03956225?

The interventions under investigation include: Systane iLux® Dry Eye System (DEVICE), LipiFlow® Thermal Pulsation System (DEVICE).

Who is sponsoring clinical trial NCT03956225?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03956225 being conducted?

This trial has 15 study locations across California, Florida, Illinois, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Meibomian Gland Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Meibomian Gland Dysfunction

All registered trials for this condition

Evaporative Dry Eye Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.